Opinion|Videos|October 22, 2024
Second-Line LR- MDS Setting: Treatment Options and Considerations
Panelists discuss how they determine thresholds for changing therapy in patients with MDS, evaluate second-line treatment options including the potential use of ESAs after luspatercept, and offer key takeaways for community colleagues managing similar clinical scenarios.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is your threshold for changing therapy in your clinical practice?
- What treatment options would you consider in the second-line setting for this patient? Do you consider trialing ESAs post luspatercept?
- What are some key takeaways you can offer community colleagues from this clinical scenario and discussion?
Advertisement
Related to this article
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
A 3-year, $225K award will focus on improving quality of life for patients living with long-term effects of cancer treatment.
China's NMPA accepted a supplemental application expanding toripalimab's perioperative NSCLC indication to stage II-III disease.
An updated HARMONi analysis showed a consistent OS benefit with ivonescimab plus chemotherapy in EGFR-mutated NSCLC.
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
Sacituzumab govitecan produced an ORR of 35% in heavily pretreated platinum-resistant ovarian cancer in a phase 2 study.
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
3
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
4
Dr Mardones on Giredestrant Plus Palbociclib in Estrogen Receptor+ Breast Cancer
5